Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Drug Pricing Reform Could Cause “Crustal Change” in Industry Structure: Chugai President
February 2, 2018
- Chugai Notches Up Record Earnings in 2017 on Bullish Exports, Milestones
February 2, 2018
- Roche Diagnostics’ ALK CDx Ventana Filed for Add’l Use for Alecensa
February 2, 2018
- Meiji’s Parkinson’s Candidate Hits Goal in Japan PII/III, Filing Planned for 2018
February 2, 2018
- IMS Japan, Quintiles Japan to Change Names in April
February 1, 2018
- Astellas Taps EVP Yasukawa as Next CEO
February 1, 2018
- Hisamitsu’s Transdermal Schizophrenia Med Hits Primary Endpoint: US PIII
February 1, 2018
- Ferring Beefing Up Reproductive Health Biz in Japan, Sets Up Specialized Sales Team
January 31, 2018
- Sunovion’s Parkinson’s Candidate Hits PIII Primary Endpoint, US Filing Set for Spring
January 31, 2018
- Pfizer Files Japan NDA for Next-Gen ALK Inhibitor Lorlatinib
January 31, 2018
- US FDA Fast-Tracks Takeda’s Zika Vaccine Candidate
January 31, 2018
- Otsuka Bags US$10 Million Grant from Gates Foundation for Development of Anti-TB Drug
January 31, 2018
- Hiroshima Couple Served with Arrest Warrant over Counterfeit Harvoni
January 30, 2018
- Novartis Seeks Ankylosing Spondylitis Nod for Cosentyx in Japan
January 30, 2018
- New GSK Japan President to Take Office on Feb. 1
January 30, 2018
- Sanofi to Launch Antibody Drug Dupilumab for Atopic Dermatitis this Spring, Sets Up Special Marketing Force for Potential Blockbuster
January 30, 2018
- New PMP Scheme Will Cause “Pause” before PIII Go/No-Go Decision: Pfizer Japan Head
January 29, 2018
- Takeda Fails in Key Actos Trial for Alzheimer’s
January 26, 2018
- Contract Sales Reps in Japan Log Largest Dip in 2017: Industry Group
January 25, 2018
- Takeda Ramps Up Inisync Pitch in November: Anterio Ranking
January 25, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…